Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of erlotinib in treating patients who have
unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib
may interfere with the growth of cancer cells and slow the growth of the tumor.